Amgen is a global biopharmaceutical company that discovers, develops, and manufactures medicines across multiple therapeutic areas including rheumatology, oncology, bone health, cardiovascular disease, and immunology. The company's portfolio includes blockbuster drugs such as Enbrel for rheumatoid arthritis, Repatha for cardiovascular risk reduction, Prolia for osteoporosis, and various cancer treatments, with products distributed through pharmaceutical wholesalers to hospitals, clinics, and pharmacies. Amgen maintains several partnership agreements with other pharmaceutical and biotech firms to expand its pipeline and commercialize treatments.
1Y: 466.01 (+60.5%) · range 288.30–466.01
entry readiness 7 · NOT READY · exit proximity 0
Value area 353.55–447.47 · 1% of 120d volume overhead · clean runway
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.115 | Oct 16, 2026 |
| congressional-trading | 0.085 | Oct 30, 2026 |
none
WEAKENING · rank 5 · none
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.79% | -1.79% | 1/20d |
| 40d | -1.79% | -1.79% | 1/40d |